The spending planned by Alphabet Inc., Amazon.com Inc., Meta Platforms Inc. and Microsoft Corp., all in pursuit of dominance ...

Voxtral Transcribe 2 consists of two speech-to-text models with transcription quality, diarization, and ultra-low latency.

Hyperscale Data (GPUS) surged nearly 20% in Monday’s premarket session after a 48.7% gain Friday on heavy volume Executive Chairman Milton C. Ault III bought 108,800 shares while Ault & Company ...

An ambitious data-center project in Utah is going to need about one-quarter of the power the entire state currently uses. David Gray, co-chief executive for the project’s developer, knows he can’t get ...

Two companies at the center of the artificial-intelligence data center investment boom are parting ways, according to a report from the Financial Times. Oracle and alternative investments firm, Blue ...

This repo contains Python code to generate the global dataset of factor returns, stock returns, and firm characteristics from “Is there a Replication Crisis in Finance?” by Jensen, Kelly, and Pedersen ...

Generac Holdings Inc (NYSE:GNRC) stock was last seen up 2.3% at $140.11, after Wells Fargo upgraded the power generator to "overweight" from "equal weight," with a price-target hike to $195 from $186.

The global competition to develop large AI models has been characterized by discussions concerning high-performance accelerated computing chips and advancements in software. However, this digital ...

This script is a Python-based tool that fetches stock data from Yahoo Finance, analyzes price trends, calculates simple moving averages (SMAS), and visualizes the results in a graph.

Artificial intelligence (AI) remains among the hottest market topics, with investors continuing to seek ways to obtain exposure. The theme has undoubtedly been one of the strongest we’ve seen in years ...

Snowflake (NYSE:SNOW) shares have surged by nearly 50% this year, although the stock fell on Thursday after the Q3 results were announced. Investors seem to be worried as product revenue growth slowed ...

Shares of Janux Therapeutics plunged after the biopharma company posted what it called “positive trial data” for a novel treatment in patients with late-stage prostate cancer.